# Oral Docetaxel in Patients With Normal or Impaired Liver Function

> **NCT05084456** · PHASE1 · WITHDRAWN · sponsor: **Modra Pharmaceuticals**

## Conditions studied

- Solid Tumor, Adult
- Impaired Liver Function

## Interventions

- **DRUG:** ModraDoc006/r

## Key facts

- **NCT ID:** NCT05084456
- **Lead sponsor:** Modra Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07
- **Primary completion:** 2020-02
- **Final completion:** 2020-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Pending further development
- **Last updated:** 2021-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05084456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05084456, "Oral Docetaxel in Patients With Normal or Impaired Liver Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05084456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*